MariMed Inc. (MRMD)
OTCQX OTCQX Primary 
MariMed Inc. (MRMD) Reports Q3 Loss, Misses Revenue Estimates
MariMed Inc. (MRMD) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to break-even earnings per share a year ago.
Despite Fast-paced Momentum, MariMed Inc. (MRMD) Is Still a Bargain Stock
MariMed Inc. (MRMD) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
MariMed Inc. (MRMD) Q2 2025 Earnings Call Transcript
MariMed Inc. (OTCQX:MRMD) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Jake Dean - Director of Research and Development Jon R. Levine - Co-Founder, CEO, President, Secretary, Treasurer & Director Mario Pinho - Chief Financial Officer Ryan Crandall - Chief Commercial Officer Conference Call Participants Andrew Semple - Ventum Financial Corp., Research Division Joseph Anthony Gomes - NOBLE Capital Markets, Inc., Research Division Pablo Ernesto Zuanic - Zuanic & Associates Operator Good morning.
MariMed Inc. (MRMD) Reports Break-Even Earnings for Q2
MariMed Inc. (MRMD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to break-even earnings per share a year ago.
MariMed Inc. (MRMD) Q1 2025 Earnings Call Transcript
MariMed Inc. (OTCQX:MRMD) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Kevin Compagna - Head of Wholesale, Sales Jon Levine - Chief Executive Officer Ryan Crandall - Chief Commercial Officer Mario Pinho - Chief Financial Officer Conference Call Participants Andrew Semple - Ventum Financial Pablo Zuanic - Zuanic & Associates Joe Gomes - Noble Capital Operator Good morning. My name is Constantine, and I will be your conference operator today.
MariMed Inc. (MRMD) Reports Q1 Loss, Lags Revenue Estimates
MariMed Inc. (MRMD) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to break-even earnings per share a year ago.
MariMed Inc. (MRMD) Q4 2024 Earnings Call Transcript
MariMed Inc. (OTCQX:MRMD) Q4 2024 - Earnings Conference Call March 6, 2025 8:00 AM ET Company Participants Sara Rosenfield - Brand Manager Jon Levine - CEO Ryan Crandall - Chief Revenue Officer Mario Pinho - CFO Conference Call Participants Andrew Semple - Ventum Financial Pablo Zuanic - Zuanic and Associates Joe Gomes - Noble Capital Operator Good morning. My name is Angeline, and I will be your conference operator today.
Is MariMed A Safe Haven In The Wake Of Florida's Cannabis Legalization Defeat?
Cannabis company MariMed Inc. MRMD released its Q3 2024 results on November 6, announcing revised guidance for the fiscal year. While the company expects an 18–20% decline in EBITDA – down from its prior projection of flat to 2% growth – it raised its sales guidance to a 6–8% increase, up from 5–7%.
MariMed Inc. (MRMD) Q3 2024 Earnings Call Transcript
MariMed Inc. (OTCQX:MRMD) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Steve West - Vice President, Investor Relations Jon Levine - Chief Executive Officer Ryan Crandall - Chief Revenue Officer Tim Shaw - Chief Operating Officer Mario Pinho - Chief Financial Officer Conference Call Participants Pablo Zuanic - Zuanic Associates Andrew Semple - Ventum Financial Jesse Redmond - Water Tower Research William McNarland - TDR Research Operator Good morning. My name is Nicole, and I will be your lead operator for today.
Can MariMed's $7.7M Illinois Cannabis Expansion Turn The Tide In A $496M Market?
In Zuanic & Associates' latest equity report, senior analyst Pablo Zuanic analyzes MariMed's MRMD performance across its core markets, with Illinois (IL) accounting for 40-45% of the company's sales.
MariMed succeeds with growth strategy prioritizing conservatism over quick wins
MariMed (OTCQX:MRMD) has captured opportunities across the cannabis value chain with its “seed-to-sale” approach, encompassing flower cultivation, product development, marketing and distribution, and retail operations in key cannabis growth markets in the US. Importantly, the company chose a deliberate and evenly paced approach over the lure of rapid expansion to reach this point.
